Navigation Links
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Date:5/8/2008

Reporting on data from 1999-2002)

(2) Carr, et al. "Efficacy and tolerability of FLECTOR(R) Patch

(diclofenac epolamine topical patch) in the treatment of minor soft

tissue injury pain." Abstract #8332. Presented May 9, 2008, at the

American Pain Society 27th Annual Meeting. (3) Rusca, et al. "Comparison of plasma pharmacokinetics of FLECTOR(R) Patch (diclofenac epolamine topical patch) and oral Voltaren(R) (diclofenac sodium enteric-coated tablets) in healthy volunteers."
Abstract #8383. Presented May 8, 2008, at the American Pain Society

27th Annual Meeting.


'/>"/>
SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)...3 /- USHIFU, LLC, the clinical trial,...napolis, IN), is pleased,to announce conditional w...col from the FDA to begin a pivotal trial for the ...nablate(R) 500 in men who have failed,external bea... of Urology at NYU School of Medicine and,medical ...
(Date:5/13/2008)...rance, May 13 /- NicOx S.A.... Inc. has initiated the,first in a series of plann...ive patients, under the companies, collaborative a...hypertensive agents using NicOx,proprietary techn...d from,the companies, joint research program, of w...
(Date:5/12/2008)..., Calif., May 12 /- Napo,Ph...es that it presented a,poster in collaboration wit...f a patient reported outcomes questionnaire focuse...spects of chronic diarrhea in persons living with,...rmacoeconomics and,Outcomes Research (ISPOR) Annua...
(Date:5/12/2008)...rcell,) to acquire Iomai Corporation (,Iomai,) in ...D 6.60 per share of Iomai,s common stock represe...pproximately USD 189 million (EUR 122 million). Ac...ock exchange for approximately 41 percent of Ioma...holders for,approximately 1.7 million Intercell sh...
Breaking Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Napo Presents at ISPOR Meeting in Toronto 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11LifeScience Alley 2007 3A German Healthcare Market Offers Gateway to Europe 7736 1LifeScience Alley 2007 3A German Healthcare Market Offers Gateway to Europe 7736 2Edison Innovation Fund Helps Tris Pharma Expand 2093 1Edison Innovation Fund Helps Tris Pharma Expand 2093 2Edison Innovation Fund Helps Tris Pharma Expand 2093 3Alpha 1 Foundation AARC Cooperate on Study to Test 5 000 COPD Patients for Alpha 1 995 1Alpha 1 Foundation AARC Cooperate on Study to Test 5 000 COPD Patients for Alpha 1 995 2Alpha 1 Foundation AARC Cooperate on Study to Test 5 000 COPD Patients for Alpha 1 995 3Common Household Chemical Could Raise Breast Cancer Risk 7733 1Common Household Chemical Could Raise Breast Cancer Risk 7733 2Common Household Chemical Could Raise Breast Cancer Risk 7733 3
...International Conference on Avian,Influenza at Fra...ewswire-FirstCall/ -- Very low doses of,Novavax In...n,against a lethal challenge of live H5N1 viruses,...ay at the Second International,Conference on Avian... microgram doses of Novavax,s,virus-like particle ...
...and Treatment of Rare but Devastating,Condition , ...versity London,and the University of Leicester and...breakthrough in the treatment of a rare but,devast...nd young,people. , In a world first, the clinician...ready treated one patient with promising,results. ...
Other Medicine Technology:Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 2Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5
(Date:5/13/2008)... 29% Revenue Increase and 45% Profit Growth, RI.../ -- Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ ...anization in Brazil, announced today its consolida... 1st QUARTER 2008 Highlights, -- ...of March, 33.3% above the same period last y...
(Date:5/13/2008)...aders Unite to Provide Comprehensive Wellness Prod... ARLINGTON, Texas, May 13 /PRNewswire/ -- Veria --...bining Veria TV (a 24x7 HD television,network), lo...ite -- today,announced its acquisition of Scottsda...vy is America,s leading provider of therapeutic ma...
(Date:5/13/2008)...n Cut in Year-Ahead Nursing Home Funding Harms Pat..., Texas, May 13 /PRNewswire-USNewswire/ -- Comment...istration,s proposed regulatory,changes that will ...y $47,million in the year ahead -- the 4th highest...are Association (THCA) today warned the Medicare f...
(Date:5/13/2008)...N.J., May 13 /PRNewswire-FirstCall/ -- TOFUTTI BRA... for the thirteen week period ended,March 29, 2008...9, 2008 decreased 4% to,$4.65 million compared wit...s ended March 31, 2007 due to the discontinuance o...eriod that were available for sale in the 2007,per...
Breaking Medicine News(10 mins):Health News:Amil Has Strong Growth With High Profitability 2Health News:Veria Announces Acquisition of Massage Envy Ltd. 2Health News:Veria Announces Acquisition of Massage Envy Ltd. 3Health News:New Study: Texas Seniors 4th Hardest-Hit from Proposed Bush Administration Medicare Cuts 2Health News:New Study: Texas Seniors 4th Hardest-Hit from Proposed Bush Administration Medicare Cuts 3Health News:TOFUTTI Announces First Quarter Results 2Health News:TOFUTTI Announces First Quarter Results 3Health News:TOFUTTI Announces First Quarter Results 4
...dical Officer of Ontario has announced that it wil...jor infectious disease outbreak. Many of Ontario's... working on a full time basis,// and provincial la... outdated equipment. The Province may be incapable...
...entists have revealed that men can be more vindict...ile women generally feel empathy when they feel sl...s of the study were published in the Nature journa... the study, which proves that the sex of the perso...
...d was declared brain dead in a hospital in Hyderab...e organs of their loved one. // MOHAN (Multi Organ...ere called in and they provided the family with em...ere being undertaken. It was late evening before a...
...lk Center at India’s Mumbai City has been providin...Center at the Sion Hospital caters// to newborns ... The deprivation of breast milk, which contains a ... digestible food for babies, could lead to lower I...
Other Medicine News:Health News:A first in Liver Transplant in India – Networking works wel 2Health News:Human Milk Center Caters To Premature Babies 2
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications.
The link classic plus hip stem for cemented primary hip replacement surgery
The uncemented hip joint prosthesis system.
The cemented hip joint prosthesis system.
Medicine Products: